These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

263 related articles for article (PubMed ID: 34831403)

  • 1. Effect of BCG Revaccination on Occupationally Exposed Medical Personnel Vaccinated against SARS-CoV-2.
    Ramos-Martinez E; Falfán-Valencia R; Pérez-Rubio G; Andrade WA; Rojas-Serrano J; Ambrocio-Ortiz E; Galicia-Álvarez DS; Bárcenas-Montiel I; Velasco-Medina A; Velázquez-Sámano G
    Cells; 2021 Nov; 10(11):. PubMed ID: 34831403
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Immunogenicity after two doses of inactivated virus vaccine in healthcare workers with and without previous COVID-19 infection: Prospective observational study.
    Yalçın TY; Topçu DI; Doğan Ö; Aydın S; Sarı N; Erol Ç; Kuloğlu ZE; Azap ÖK; Can F; Arslan H
    J Med Virol; 2022 Jan; 94(1):279-286. PubMed ID: 34468990
    [TBL] [Abstract][Full Text] [Related]  

  • 3. BNT162b2 COVID-19 vaccine and correlates of humoral immune responses and dynamics: a prospective, single-centre, longitudinal cohort study in health-care workers.
    Lustig Y; Sapir E; Regev-Yochay G; Cohen C; Fluss R; Olmer L; Indenbaum V; Mandelboim M; Doolman R; Amit S; Mendelson E; Ziv A; Huppert A; Rubin C; Freedman L; Kreiss Y
    Lancet Respir Med; 2021 Sep; 9(9):999-1009. PubMed ID: 34224675
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The effect of BCG revaccination on all-cause mortality beyond infancy: 30-year follow-up of a population-based, double-blind, randomised placebo-controlled trial in Malawi.
    Glynn JR; Dube A; Fielding K; Crampin AC; ; Kanjala C; Fine PEM
    Lancet Infect Dis; 2021 Nov; 21(11):1590-1597. PubMed ID: 34237262
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Evidence for the heterologous benefits of prior BCG vaccination on COVISHIELD™ vaccine-induced immune responses in SARS-CoV-2 seronegative young Indian adults.
    Rakshit S; Adiga V; Ahmed A; Parthiban C; Chetan Kumar N; Dwarkanath P; Shivalingaiah S; Rao S; D'Souza G; Dias M; Maguire TJA; Doores KJ; Zoodsma M; Geckin B; Dasgupta P; Babji S; van Meijgaarden KE; Joosten SA; Ottenhoff THM; Li Y; Netea MG; Stuart KD; De Rosa SC; McElrath MJ; Vyakarnam A
    Front Immunol; 2022; 13():985938. PubMed ID: 36268023
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Neutralization of alpha, gamma, and D614G SARS-CoV-2 variants by CoronaVac vaccine-induced antibodies.
    Fernández J; Bruneau N; Fasce R; Martín HS; Balanda M; Bustos P; Ulloa S; Mora J; Ramírez E
    J Med Virol; 2022 Jan; 94(1):399-403. PubMed ID: 34460119
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A human cell-based SARS-CoV-2 vaccine elicits potent neutralizing antibody responses and protects mice from SARS-CoV-2 challenge.
    He X; Ding L; Cao K; Peng H; Gu C; Li Y; Li D; Dong L; Hong X; Wang X; Fu M; Qiu C; Zhu C; Zhang Z; Song S; Wang C; Jiang Z; Xie Y; Qi Z; Zhao C; Zhao P; Zhang X; Xu J
    Emerg Microbes Infect; 2021 Dec; 10(1):1555-1573. PubMed ID: 34304724
    [TBL] [Abstract][Full Text] [Related]  

  • 8. BNT162b2 Vaccination Elicits Strong Serological Immune Responses Against SARS-CoV-2 Including Variants of Concern in Elderly Convalescents.
    Jahrsdörfer B; Fabricius D; Scholz J; Ludwig C; Grempels A; Lotfi R; Körper S; Adler G; Schrezenmeier H
    Front Immunol; 2021; 12():743422. PubMed ID: 34659239
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Protective Immunity against Gamma and Zeta Variants after Inactivated SARS-CoV-2 Virus Immunization.
    Fumagalli MJ; Castro-Jorge LA; Fraga-Silva TFC; de Azevedo PO; Capato CF; Rattis BAC; Hojo-Souza NS; Floriano VG; de Castro JT; Ramos SG; da Fonseca BAL; Bonato VLD; Gazzinelli RT; Figueiredo LTM
    Viruses; 2021 Dec; 13(12):. PubMed ID: 34960708
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Immunogenicity of COVID-19 Tozinameran Vaccination in Patients on Chronic Dialysis.
    Schrezenmeier E; Bergfeld L; Hillus D; Lippert JD; Weber U; Tober-Lau P; Landgraf I; Schwarz T; Kappert K; Stefanski AL; Sattler A; Kotsch K; Dörner T; Sander LE; Budde K; Halleck F; Kurth F; Corman VM; Choi M
    Front Immunol; 2021; 12():690698. PubMed ID: 34276681
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Lessons From Bacille Calmette-Guérin for SARS-CoV-2 Vaccine Candidates.
    Behr MA; Divangahi M; Schurr E
    J Infect Dis; 2021 Feb; 223(2):189-191. PubMed ID: 33535239
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Robust Neutralizing Antibody Levels Detected after Either SARS-CoV-2 Vaccination or One Year after Infection.
    Glöckner S; Hornung F; Baier M; Weis S; Pletz MW; Deinhardt-Emmer S; Löffler B; The CoNAN Study Group
    Viruses; 2021 Oct; 13(10):. PubMed ID: 34696428
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Using BCG vaccine to enhance non-specific protection of health care workers during the COVID-19 pandemic: A structured summary of a study protocol for a randomised controlled trial in Denmark.
    Madsen AMR; Schaltz-Buchholzer F; Benfield T; Bjerregaard-Andersen M; Dalgaard LS; Dam C; Ditlev SB; Faizi G; Johansen IS; Kofoed PE; Kristensen GS; Loekkegaard ECL; Mogensen CB; Mohamed L; Ostenfeld A; Oedegaard ES; Soerensen MK; Wejse C; Jensen AKG; Nielsen S; Krause TG; Netea MG; Aaby P; Benn CS
    Trials; 2020 Sep; 21(1):799. PubMed ID: 32943115
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Heterologous ChAdOx1 nCoV-19 and mRNA-1273 Vaccination.
    Normark J; Vikström L; Gwon YD; Persson IL; Edin A; Björsell T; Dernstedt A; Christ W; Tevell S; Evander M; Klingström J; Ahlm C; Forsell M
    N Engl J Med; 2021 Sep; 385(11):1049-1051. PubMed ID: 34260850
    [No Abstract]   [Full Text] [Related]  

  • 15. SARS-CoV-2 vaccines for all but a single dose for COVID-19 survivors.
    Frieman M; Harris AD; Herati RS; Krammer F; Mantovani A; Rescigno M; Sajadi MM; Simon V
    EBioMedicine; 2021 Jun; 68():103401. PubMed ID: 34051441
    [No Abstract]   [Full Text] [Related]  

  • 16. BCG vaccination history associates with decreased SARS-CoV-2 seroprevalence across a diverse cohort of health care workers.
    Rivas MN; Ebinger JE; Wu M; Sun N; Braun J; Sobhani K; Van Eyk JE; Cheng S; Arditi M
    J Clin Invest; 2021 Jan; 131(2):. PubMed ID: 33211672
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Different Profiles of Antibodies and Cytokines Were Found Between Severe and Moderate COVID-19 Patients.
    Guo Y; Li T; Xia X; Su B; Li H; Feng Y; Han J; Wang X; Jia L; Bao Z; Li J; Liu Y; Li L
    Front Immunol; 2021; 12():723585. PubMed ID: 34489974
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Serum Neutralizing Activity of mRNA-1273 against SARS-CoV-2 Variants.
    Choi A; Koch M; Wu K; Dixon G; Oestreicher J; Legault H; Stewart-Jones GBE; Colpitts T; Pajon R; Bennett H; Carfi A; Edwards DK
    J Virol; 2021 Nov; 95(23):e0131321. PubMed ID: 34549975
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Antibody-dependent neutralizing capacity of the SARS-CoV-2 vaccine BNT162b2 with and without previous COVID-19 priming.
    Hansen CB; Jarlhelt I; Hasselbalch RB; Hamm SR; Fogh K; Pries-Heje MM; Møller DL; Heftdal LD; Pérez-Alós L; Sørensen E; Larsen MAH; Skjoedt MO; Ostrowski SR; Frikke-Schmidt R; Bayarri-Olmos R; Hilsted LM; Bundgaard H; Nielsen SD; Iversen KK; Garred P
    J Intern Med; 2021 Dec; 290(6):1272-1274. PubMed ID: 34237190
    [No Abstract]   [Full Text] [Related]  

  • 20. Antibody response elicited by a third boost dose of inactivated SARS-CoV-2 vaccine can neutralize SARS-CoV-2 variants of concern.
    Yue L; Zhou J; Zhou Y; Yang X; Xie T; Yang M; Zhao H; Zhao Y; Yang T; Li H; Xiang H; Wang J; Lu S; Liu H; Zhao H; Wei X; Zhang Y; Xie Z
    Emerg Microbes Infect; 2021 Dec; 10(1):2125-2127. PubMed ID: 34666622
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 14.